A review of gene therapy for Duchenne muscular dystrophy.
- Author:
Qi-Chao DONG
1
;
Hui-Min CHEN
;
Xin JIN
Author Information
1. Medical School of Shaoxing University, Shaoxing, Zhejiang 312000, China. zjujx@qq.com.
- Publication Type:Journal Article
- From:
Chinese Journal of Contemporary Pediatrics
2018;20(8):691-696
- CountryChina
- Language:Chinese
-
Abstract:
Duchenne muscular dystrophy (DMD) is an X-linked recessive hereditary disease caused by mutations in the DMD gene that encodes dystrophin. It is characterized by progressive muscle weakness and degeneration of skeletal muscle and myocardium due to the absence of dystrophin. The disease often occurs at the age of 2-5 years, and most children may die of heart failure or respiratory insufficiency at the age of around 20 years. At present, supportive therapy is often used in clinical practice to improve symptoms, but this cannot improve the outcome of this disease. The development of gene therapy brings new hope to the cure of this disease. This article summarizes gene replacement therapy for DMD, including the research advances in DMD gene transduction technology mediated by adeno-associated virus, utrophin protein upregulation technology, and clustered regularly interspaced short palindromic repeat gene editing technology, and reviews the recommendations to solve the issues of adeno-associated viral load, long-term effective expression of transgenic products, and utrophin protein expression, in order to provide a reference for further research.
